Boston Scientific’s Q2 Earnings Call: Our Top 5 Analyst Questions
Boston Scientific (BSX) reported Q2 revenue of $5.44B vs $5.36B estimates and adjusted EPS of $0.86 vs $0.83. Management said Interventional Cardiology, Endoscopy and Neuromodulation grew, while Electrophysiology and WATCHMAN slowed. CEO Michael Mahoney cited U.S. WATCHMAN market changes and competition, leading to lower Q3 revenue guidance and reduced full-year adjusted EPS midpoint to $3.30.
How this was made
The 30-second read
Why it matters
Traders should focus on the guidance reset and the stated drivers of WATCHMAN volume declines, plus the planned 2027-2028 product launches and restructuring reinvestment that could change the growth trajectory.
Market read
Despite revenue and adjusted EPS beats, the company cut Q3 revenue and full-year adjusted EPS guidance, making this a near-term estimate-revision catalyst.
What to watch
The article highlights integration progress and restructuring phasing, which may improve profitability even if top-line growth is temporarily constrained.
Background
The piece summarizes Boston Scientific’s Q2 call, emphasizing segment divergence and management’s more cautious outlook tied to WATCHMAN and Electrophysiology.
Ticker impact
Boston Scientific guided Q3 revenue to $5.27B midpoint and cut full-year adjusted EPS to $3.30, citing WATCHMAN and Electrophysiology weakness.
Near-term downside bias versus prior expectations; upside depends on execution of 2027-2028 product launches and any stabilization in WATCHMAN volumes.
The article provides specific, time-bound guidance changes and management explanations tied directly to WATCHMAN and Electrophysiology trends, which typically drive revisions to earnings estimates and positioning.
Market effects
Signals continued competitive and adoption pressure in structural heart and electrophysiology, while interventional cardiology and endoscopy remain resilient.
Focuses on U.S. WATCHMAN dynamics, implying U.S. procedure volumes and competitive intensity are the main swing factor.
Limited explicit global read-through beyond product launch timelines and integration progress.
Counterpoint
Interventional Cardiology, Endoscopy, and Neuromodulation growth plus margin expansion could offset WATCHMAN weakness if the product-launch pipeline accelerates.
Key entities
- companyBoston Scientific
Subject of the article, with Q2 results and guidance changes tied to WATCHMAN and Electrophysiology trends.
- executiveMichael Mahoney
CEO quoted explaining the guidance reset drivers and WATCHMAN competitive outlook.
- executiveJonathan Monson
CFO quoted on restructuring cost savings phasing and reinvestment plans.
- executiveDr. Ken Stein
Chief Medical Officer quoted on education, expanded indications, and clinical trials to support WATCHMAN growth.
